ArticlePsychopharmacology2017
Brexpiprazole reduces hyperactivity, impulsivity, and risk-preference behavior in mice with dopamine transporter knockdown-a model of mania.
Article in Psychopharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Dopamine transporter knockdown mice in the behavioral pattern monitor: A robust, reproducible model for mania-relevant behaviors.Pharmacology, biochemistry, and behavior · 2019Pooled it
- Evidence for pro-cognitive benefits of cannabinoids in people with bipolar disorder.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Trial
- Histamine HMolecular psychiatry · 2026Article
- Chemogenetic inhibition of the anterior cingulate cortex increases safe decision-making in aged mice performing the Iowa Gambling Task.Psychopharmacology · 2026Article
- Chronic cannabis use in people with bipolar disorder is associated with comparable decision-making and functional outcome to healthy participants.Translational psychiatry · 2025Article
- Brexpiprazole for agitation in alzheimer's disease: A systematic review and meta-analysis of randomized controlled trials.Indian journal of psychiatry · 2025Review
- Doxycycline reversal of amphetamine-induced mania-like behavior is related to adjusting brain monoamine abnormalities and antioxidant effects in primary hippocampal neurons.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- iTat transgenic mice exhibit hyper-locomotion in the behavioral pattern monitor after chronic exposure to methamphetamine but are unaffected by Tat expression.Pharmacology, biochemistry, and behavior · 2023Article
- Chronic antipsychotic treatment exerts limited effects on the mania-like behavior of dopamine transporter knockdown mice.Behavioural brain research · 2021Article
- Chronic nicotine, but not suramin or resveratrol, partially remediates the mania-like profile of dopamine transporter knockdown mice.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2021Article
- Reduced Plasma Dopamine-β-Hydroxylase Activity Is Associated With the Severity of Bipolar Disorder: A Pilot Study.Frontiers in psychiatry · 2021Article
- Challenges and Opportunities in Animal Models of Gambling-like Behavior.Current opinion in behavioral sciences · 2020Article
- Convergent neural substrates of inattention in bipolar disorder patients and dopamine transporter-deficient mice using the 5-choice CPT.Bipolar disorders · 2020Article
- Monoaminergic modulation of decision-making under risk of punishment in a rat model.Behavioural pharmacology · 2018Article
- Blockade of dopamine DJournal of psychopharmacology (Oxford, England) · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 3 countries.
Funding
Abstract
rationaleBipolar disorder (BD) is a unique mood disorder defined by periods of depression and mania. The defining diagnosis of BD is the presence of mania/hypomania, with symptoms including hyperactivity and risk-taking. Since current treatments do not ameliorate cognitive deficits such as risky decision-making, and impulsivity that can negatively affect a patient's quality of life, better treatments are needed.
objectivesHere, we tested whether acute treatment with brexpiprazole, a serotonin-dopamine activity modulator with partial agonist activity at D
methodsThe effects of brexpiprazole on DAT knockdown and wild-type littermate mice were examined in the behavioral pattern monitor (BPM) and Iowa gambling task (IGT) to quantify activity/exploration and impulsivity/risk-taking behavior respectively.
resultsDAT knockdown mice exhibited hyper-exploratory behavior in the BPM and made fewer safe choices in the IGT. Brexpiprazole attenuated the mania-like hyper-exploratory phenotype and increased safe choices in risk-preferring DAT knockdown mice. Brexpiprazole also reduced safe choices in safe-preferring mice irrespective of genotype. Finally, brexpiprazole reduced premature (impulsive-like) responses in both groups of mice.
conclusionsConsistent with earlier reports, DAT knockdown mice exhibited hyper-exploratory, risk-preferring, and impulsive-like profiles consistent with patients with BD mania in these tasks. These behaviors were attenuated after brexpiprazole treatment. These data therefore indicate that brexpiprazole could be a novel treatment for BD mania and/or risk-taking/impulsivity disorders, since it remediates some relevant behavioral abnormalities in this mouse model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.